SEC Form 4 · accession 0001192482-15-000394
Zynerba Pharmaceuticals, Inc. · ZYNE
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Richard A Baron
Officer — Chief Financial Officer
Period of report
Sep 11, 2015
Accepted (ET)
Sep 15, 2015 · 1:48 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001621443
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Sep 11, 2015 | M | 15,957 | $3.98 | A | 15,957 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock OptionF1 | $3.98 | Sep 11, 2015 | M | 15,957 | D | — | Jan 2, 2025 | Common Stock | 15,957 | 47,872 | D |
Explanation of responses
- F1The stock option vested as to 25% of the common stock (15,957 shares) as of the date of the closing of the Issuer's initial public offering, with the balance vesting in twelve equal quarterly installments thereafter.